07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

ExperGen, Thallion cancer news

Thallion said a binding arbitration proceeding has been started related to a dispute with ExperGen over TLN-232 (CAP-232), which Thallion (formerly Caprion Pharmaceuticals Inc. ) licensed from ExperGen in 2006. ExperGen alleges that Thallion was...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Company News

Expergen GmbH, Thallion cancer news

The companies settled a dispute regarding CAP-232, which Caprion Pharmaceuticals Inc. (now Thallion) licensed from Expergen in 2006 (see BioCentury, March 20, 2006). Thallion said Expergen alleged that Thallion did not pay a US$200,000 license...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Caprion, Ecopia deal

EIA and Caprion completed their previously announced merger and raised C$45 million (US$38.4 million) in a private placement (see BioCentury, Jan. 8). The newco will be called Thallion Pharmaceuticals Inc. and will trade on the...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Company News

Axcan management update

Axcan Pharma Inc. (TSX:AXP; AXCA), Mont St. Hilaire, Quebec   Business: Gastrointestinal   Departing: Alexandre LeBeaut as SVP and CSO   Hired: Marc Riviere as VP of clinical development, formerly SVP of clinical development at...
08:00 , Jan 8, 2007 |  BC Week In Review  |  Company News

Caprion, Ecopia deal

EIA and Caprion will merge, contingent upon completion of a C$30 million ($25.7 million) private placement. Caprion shareholders will receive 69.9 million EIA shares, representing 50% of the newco's total shares outstanding after the placement....
08:00 , Oct 30, 2006 |  BC Week In Review  |  Company News

Caprion, Vertex deal

The companies expanded an April deal, under which Caprion is using its CellCarta proteomics technology to identify pharmacodynamic biomarkers in samples from preclinical and clinical studies conducted by VRTX (see BioCentury, April 3). Caprion will...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Company News

Caprion, Goodwin deal

Goodwin will manufacture Caprion's Shigamabs to treat Shiga toxin-producing E. coli infection. The product, which consist of two chimeric monoclonal antibodies against Shiga toxin, has completed Phase I testing. Caprion hopes to begin Phase II/III...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Caprion, J&J deal

JNJ's Centocor Inc. subsidiary received exclusive, worldwide rights to develop and commercialize monoclonal antibodies and other therapeutics against cancer targets from Caprion. The targets were discovered using Caprion's CellCarta proteomics technology platform. Caprion will receive...
07:00 , May 15, 2006 |  BC Week In Review  |  Clinical News

Shigamabs regulatory update

FDA granted Fast Track designation for Shigamabs to treat Shiga toxin-producing bacterial infections. Shigamabs consists of chimeric monoclonal antibodies caStx1 and caStx2 against Shiga-toxin, and has Orphan Drug designations in the U.S. and the EU....
07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

Caprion, Vertex deal

Caprion will use its CellCarta proteomics technology to identify pharmacodynamic biomarkers in samples from preclinical and clinical studies conducted by VRTX. Further terms were not disclosed. Caprion Pharmaceuticals Inc. , Montreal, Quebec   Vertex Pharmaceuticals...